Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma

Recurrent Adult Soft Tissue Sarcoma Clinical Trial

Official title:

A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00720174
• Other study ID #: NCI-2009-00285
• Secondary ID: NCI-2009-00285UC
• Status: Completed
• Phase: Phase 1
• First received: July 19, 2008
• Last updated: May 16, 2016
• Start date: June 2008

Study information

• Verified date: May 2016
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This phase I trial is studying the side effects and best dose of cixutumumab given together with doxorubicin hydrochloride and to see how well they work in treating patients with unresectable, locally advanced, or metastatic soft tissue sarcoma. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving monoclonal antibody cixutumumab together with doxorubicin hydrochloride may kill more tumor cells.

Description:

PRIMARY OBJECTIVES:

I. To collect safety data about the combination of doxorubicin and Cixitumumab and determine if they can be combined with acceptable toxicity at full doses.

SECONDARY OBJECTIVES:

I. To assess the confirmed response rate (CR + PR as defined by RECIST) of patients with locally advanced or metastatic soft tissue sarcoma when treated with combination doxorubicin and Cixitumumab II. To assess the 3 and 6 month progression free survival rate of patients treated with doxorubicin and Cixitumumab.

III. To assess the progression free survival and overall survival of patients treated with doxorubicin and Cixitumumab.

IV. To evaluate changes in left ventricular ejection fraction assessed by MUGA scan after 2, 4 and 6 cycles of therapy compared to baseline.

OUTLINE: This is a multicenter, dose-escalation study of anti-IGF-1R recombinant monoclonal antibody cixutumumab.

Patients receive cixutumumab intravenously (IV) over 1 hour on days 1, 8, and 15 and doxorubicin hydrochloride IV continuously over 44-52 hours beginning on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may continue to receive cixutumumab in the absence of disease progression or unacceptable toxicity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. primary completion date: January 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed soft tissue sarcoma

• Unresectable disease

• Locally advanced or metastatic disease

• The following tumor types are not allowed:

• Embryonal and alveolar rhabdomyosarcoma

• Gastrointestinal stromal tumor

• Alveolar soft part sarcoma

• Clear cell sarcoma

• Measurable disease, defined as = 1 unidimensionally measurable lesion = 20 mm by conventional techniques or = 10 mm by spiral CT scan

• No more than 1 prior therapy for sarcoma

• No known brain metastases

• ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%

• ANC = 1,500/µL

• Platelet count = 100,000/µL

• Leukocytes = 3,000/µL

• Total bilirubin = upper limit of normal(ULN)

• AST and ALT = 2.5 times ULN

• Creatinine = 1.5 times ULN OR creatinine clearance = 60 mL/min

• Fasting serum glucose < 120 mg/dL OR below ULN

• LVEF = 50% by MUGA scan

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception during and for 3 months after the last dose of anti-IGF-1R recombinant monoclonal antibody IMC-A12

• No history of allergic reactions attributed to compounds of similar chemical or biological composition to anti-IGF-1R recombinant monoclonal antibody IMC-A12

• No poorly controlled diabetes mellitus

• Patients with a history of diabetes mellitus are eligible provided their blood glucose is within normal range and they are on a stable dietary or therapeutic regimen for this condition

• No concurrent uncontrolled illness including, but not limited to, any of the following:

• Ongoing or active infection

• Symptomatic congestive heart failure

• Unstable angina pectoris

• Cardiac arrhythmia

• Psychiatric illness or social situation that would preclude compliance with study requirements

• No other concurrent investigational or commercial agents or therapies

• Recovered from all prior therapy

• More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)

• More than 4 weeks since prior major surgery, hormonal therapy (other than replacement), or hormonal therapy

• No prior radiotherapy to the heart, mediastinum, or chest wall

• No prior anthracycline therapy or anti-IGF-1R therapy

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Adult Angiosarcoma
• Adult Desmoplastic Small Round Cell Tumor
• Adult Epithelioid Sarcoma
• Adult Extraskeletal Myxoid Chondrosarcoma
• Adult Extraskeletal Osteosarcoma
• Adult Fibrosarcoma
• Adult Leiomyosarcoma
• Adult Liposarcoma
• Adult Malignant Mesenchymoma
• Adult Malignant Peripheral Nerve Sheath Tumor
• Adult Rhabdomyosarcoma
• Adult Synovial Sarcoma
• Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone
• Childhood Angiosarcoma
• Childhood Desmoplastic Small Round Cell Tumor
• Childhood Epithelioid Sarcoma
• Childhood Fibrosarcoma
• Childhood Leiomyosarcoma
• Childhood Liposarcoma
• Childhood Malignant Mesenchymoma
• Childhood Malignant Peripheral Nerve Sheath Tumor
• Childhood Pleomorphic Rhabdomyosarcoma
• Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features
• Childhood Synovial Sarcoma
• Chondrosarcoma
• Dermatofibrosarcoma
• Dermatofibrosarcoma Protuberans
• Desmoplastic Small Round Cell Tumor
• Fibrosarcoma
• Hemangiopericytoma
• Histiocytoma, Malignant Fibrous
• Leiomyosarcoma
• Liposarcoma
• Liver Neoplasms
• Malignant Adult Hemangiopericytoma
• Malignant Childhood Hemangiopericytoma
• Metastatic Childhood Soft Tissue Sarcoma
• Nerve Sheath Neoplasms
• Neurilemmoma
• Neurofibroma
• Osteosarcoma
• Previously Treated Childhood Rhabdomyosarcoma
• Recurrent Adult Soft Tissue Sarcoma
• Recurrent Childhood Rhabdomyosarcoma
• Recurrent Childhood Soft Tissue Sarcoma
• Rhabdomyosarcoma
• Sarcoma
• Sarcoma, Synovial
• Stage III Adult Soft Tissue Sarcoma
• Stage IV Adult Soft Tissue Sarcoma
• Untreated Childhood Rhabdomyosarcoma

Intervention

Biological:
• Cixutumumab
Given IV

Drug:
• Doxorubicin Hydrochloride
Given IV

Other:
• Laboratory Biomarker Analysis
Correlative studies

Locations

Country	Name	City	State
United States	University of Michigan Comprehensive Cancer Center	Ann Arbor	Michigan
United States	University of Maryland/Greenebaum Cancer Center	Baltimore	Maryland
United States	University of Chicago Comprehensive Cancer Center	Chicago	Illinois
United States	Decatur Memorial Hospital	Decatur	Illinois
United States	NorthShore University HealthSystem-Evanston Hospital	Evanston	Illinois
United States	Fort Wayne Medical Oncology and Hematology Inc-Parkview	Fort Wayne	Indiana
United States	Ingalls Memorial Hospital	Harvey	Illinois
United States	Joliet Oncology-Hematology Associates Limited	Joliet	Illinois
United States	Loyola University Medical Center	Maywood	Illinois
United States	Froedtert and the Medical College of Wisconsin	Milwaukee	Wisconsin
United States	Illinois CancerCare-Peoria	Peoria	Illinois
United States	Mercy Hospital Saint Louis	Saint Louis	Missouri
United States	Central Illinois Hematology Oncology Center	Springfield	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximally tolerated dose (MTD) of cixitumumab when administered in a combination regimen with fixed dose doxorubicin hydrochloride, in patients with locally advanced or metastatic soft tissue sarcoma	The MTD is defined as the dose of Cixitumumab that induces dose-limiting toxicity (DLT) in no more than 20% of patients.	Up to 2 courses of treatment	Yes
Secondary	Changes in cardiac function as measured by MUGA scans of the left ventricular ejection fraction		Baseline to 6 courses of treatment	No
Secondary	Confirmed response rate (CR + PR) for comparison with doxorubicin treatment in similar historical patient populations	The mean response probability with 90% credible interval will be reported for those patients treated at the dose of cixitumumab found to be the MTD.	Up to 6 months	No
Secondary	Overall survival	Will be estimated using the product-limit method Kaplan and Meier. With point-wise estimates for the 3 and 6-month survival proportions reported with 95% confidence intervals using Greenwood's formula for calculation of the variance.	Until death due to any cause, or loss to follow-up, assessed up to 6 months	No
Secondary	Progression-free survival	Will be estimated using the product-limit method Kaplan and Meier. With point-wise estimates for the 3 and 6-month progression-free survival proportions reported with 95% confidence intervals using Greenwood's formula for calculation of the variance.	Until documented disease progression or death or loss-to-follow-up, assessed up to 6 months	No